Therapeutic Asset Ratings
128 results matching 1 filter
133,990 assets · 8,802 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
shr2554
Follicular Lymphoma
Jiangsu HengRui Medicine Co., Ltd.
P2
CCC
(48)
Tiselizumab
Follicular Lymphoma
Tianjin Medical University Cancer Institute and Hospital
P2
CCC
(48)
Tucidinostat
Follicular Lymphoma
The First Affiliated Hospital of Xiamen University
P2
CCC
(48)
VINDESINE
Follicular Lymphoma
Zhejiang Cancer Hospital
P2
CCC
(48)
Zeprumetostat
Follicular Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
P2
CCC
(48)
Adebrelimab
Follicular Lymphoma
Immunitas Therapeutics
P1/2
CC
(41)
Bgb-16673
Follicular Lymphoma
BeiGene
P1/2
CC
(41)
bn301
Follicular Lymphoma
BioNova Pharmaceuticals (Shanghai) LTD.
P1/2
CC
(41)
br1733
Follicular Lymphoma
Shanghai Blueray Biopharma Co., Ltd.
P1/2
CC
(41)
cd19-ucart
Follicular Lymphoma
University Hospital Heidelberg
P1/2
CC
(41)
ctx112
Follicular Lymphoma
CRISPR Therapeutics AG
P1/2
CC
(41)
Cytokine-Treated Veto Cells
Follicular Lymphoma
M.D. Anderson Cancer Center
P1/2
CC
(41)
eo2463
Follicular Lymphoma
Enterome
P1/2
CC
(41)
ETOPOSIDE
Follicular Lymphoma
Genmab
P1/2
CC
(41)
Fruquintinib
Follicular Lymphoma
Immunitas Therapeutics
P1/2
CC
(41)
il-15
Follicular Lymphoma
Medical College of Wisconsin
P1/2
CC
(41)
immunoglobulin G1-kappa, anti-[Homo sapiens KLRB1 (killer cell lectin like receptor B1, NKR-P1A, natural killer cell surface protein P1A, CLEC5B, CD161)], Homo sapiens monoclonal antibody; gamma1 heavy chain Homo sapiens (1-450) [VH (Homo sapiens IGHV3-23*01 (96.9%) -(IGHD) -IGHJ4*01 (85.7%), Q120>R (113), CDR-IMGT [8.8.14] (26-33.51-58.97-110)) (1-121) -Homo sapiens IGHG1*01, G1m17,1 CH1 K120, CH3 D12, L14, G1v29 CH2 A84.4 (CH1 K120 (218) (122-219), hinge 1-15 (220-234), CH2 G1v29 CH2 N84.4>A (301) (235-344), CH3 D12 (360), L14 (362) (345-449), CHS K2>del (450)) (122-450)], (224-214')-disulfide with kappa light chain Homo sapiens (1'-214') [V-KAPPA (Homo sapiens IGKV1-12*01 (94.7%) -IGKJ4*01 (91.7%), CDR-IMGT [6.3.9] (27'-32'.50'-52'.89'-97')) (1'-107') -Homo sapiens IGKC*01 (100%), Km3, A45.1 (153'), V101 (191') (108'-214')]; dimer (230-230'':233-233'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, cell line CHO-K1 lacking the glutamine synthetase (GS-KO) gene, non-glycosylated
Follicular Lymphoma
Immunitas Therapeutics
P1/2
CC
(41)
Rhil-7
Follicular Lymphoma
Medical College of Wisconsin
P1/2
CC
(41)
VNX-101
Follicular Lymphoma
Vironexis Biotherapeutics Inc.
P1/2
CC
(41)
ace1831
Follicular Lymphoma
Acepodia Biotech, Inc.
P1
CC
(40)
Car-20/19-T Cells
Follicular Lymphoma
Medical College of Wisconsin
P1/2
CC
(40)
Abbv-319
Follicular Lymphoma
AbbVie
P1
C
(37)
BP1002
Follicular Lymphoma
Bio-Path Holdings, Inc.
P1
C
(37)
Car.K.28
Follicular Lymphoma
UNC Lineberger Comprehensive Cancer Center
P1
C
(37)
cd19.20.22 car t cells
Follicular Lymphoma
University of Maryland, Baltimore
P1
C
(37)
Showing 76 to 100 of 128 assets
Previous
Page 4 of 6
Next
